We’ve brought together commercial leaders, researchers and biotechnology experts that will transform therapeutics development.
AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including:
We’re developing products at the intersection of biomaterials and pharmaceuticals.
In addition to co-founders Mike Cooke and Molly Shoichet, our board is made up of the following:
AmacaThera collaborates with University Health Network to evaluate the economic impact of post-surgical opioid use. They are developing non-opioid analgesic, AMT-143, aiming to reduce the reliance on opioid medications.Read more
AmacaThera Inc today announced that the first subjects have been dosed in the company's Phase 1 first-in-human clinical investigation of the safety of AmacaGel™.Read more
AmacaThera has received grant funding from the Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma.Read more